Brian Carothers - Vice President and General Manager, Nucleic Acid Solutions Division, Agilent
Bio coming soon!
Andrew Mitchell - Senior Director, Business Development
Joined BioVectra in 2017 as the European Business Development Manager
Promoted to BioVectra’s Senior Director, Business Development in 2020
30 years of experience in the global pharmaceutical & fine chemical area
Experience in synthesis, and fermentation covering both CDMO and Generics industries
Worked with a number of organizations, with various specialized capabilities such as large scale chromatography, energetic chemistry, biocatalysis, high containment & microbial fermentation of small molecules
Normand Blais– Chief Science Officer
20+ years at GSK leading work on multiple vaccine programs
Recently held positions in industry include: Senior Director (Function Head) Protein Biochemistry; Director Antigen Design & Prototype Production; and, Lab Head, Antigen Design and Protein Characterization.
Key areas of expertise are:
Vaccinology and technical development of Biologics
Recombinant protein expression systems and purification
Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles production
Protein Engineering and Structural Biology
Leveraging and interpreting protein biophysical attributes and analytics
Post graduate studies in Functional Genomics (Université Laval) and Bioinformatics (MIT); M.Sc. Microbiology and Immunology (Laval).
Bachelor of Science in Engineering, US Military Academy at West Point.
Captain, US Army (Artillery): Six years active duty in Germany, Oklahoma & Hawaii.
Thirty years of progressive responsibility in regulated industry, including: Large Molecule Manufacturing; API Manufacturing; Drug Product, Cosmetics, Nutraceuticals; Pharmaceutical Manufacturing; Diagnostic Lab Operations; Medical Devices; and, Nuclear Power Piping.
Executive level experience in Manufacturing Operations, Quality Operations, Supply Chain, Engineering, Finance, and Strategy.
Fifteen years of experience as Vice President / General Manager across four companies and six sites.
Scott Doncaster - Vice President, Manufacturing, Technology & Engineering
B.Sc. in Biochemistry from Mount Allison University in 1990.
Worked towards a Masters program in Biochemistry at Queens University from 1991-1994.
Worked for the Hunter Group in Aurora, Ontario from 1994-1995 in developing and supervising high purity solvent distillation processes.
Joined BIOVECTRA in 1995, supervising the enzyme and natural products bioextraction processes.
Promoted to Operations Manager in 2000 and served in that position until 2003.
Served as capital project manager for the BIOVECTRA API facility in 2001-2002.
Took the position as Director of Operations for Atlantis BioActives in 2003 to oversee the capital installation, start-up and commercial extraction process for natural taxanes.
Promoted to Director of Manufacturing for BIOVECTRA in 2005.
Appointed to Vice President, Manufacturing Technologies & Engineering in 2014.
Bryan Lowery - Vice President & General Manager, mRNA Vaccine and pDNA Operations (Interim)
BSc in Nuclear Engineering Technology (Thomas Edison College), MSQA (California State University), and MBA (Webster University).
Seventeen years of experience in pharmaceutical / biopharmaceuticals sector, including CDMO Manufacturing
Twelve years operational leadership experience in manufacturing and CDMO operations
Specialization in Change Management and Operations transformational leadership with focus on Lean/Six Sigma
Nuclear Engineering Lead Petty Officer and Nuclear Operations Instructor with the US Navy
Mark Wellman - Vice President and General Manager, Complex Chemistry Operations
M.Sc. Degree from Memorial University of Newfoundland in 1996.
Over 20 years experience with BIOVECTRA over which time he has contributed as a team member towards the development of fine chemicals, advanced intermediates, and active pharmaceutical ingredients.
Held the positions of Research Scientist (1996), Product Manager (2001), Custom Synthesis Project Manager (2003) and Manufacturing Manager, Special Projects (2005). He has participated or successfully led several API manufacturing projects to completion.
Promoted to Director of Biotech Operations in 2009.
Appointed to Vice President, Manufacturing in 2014.
Appointed to Vice President & General Manager, Complex Chemistry in 2020.
Peter Phillips - Vice President, Quality Operations
Bachelor of Science, Chemistry from the University of Calgary.
More than 25 years pharmaceutical experience in QC, QA, and R&D.
More than 20 years experience in leading QC and QA teams.
In 1997 was appointed Director of QC at Taro Pharmaceuticals, in 2005 was appointed Director QA at Taro Pharmaceuticals and in 2007 was appointed Director Quality (QA/QC) at Ranbaxy Pharmaceuticals.
Joined BIOVECTRA in January 2016 as Vice President, Quality Operations
Sean McCluskey - Vice President IT & Digitization
Electronics Engineering (Yorkville University)
Over 30 years of Experience in IT and Digital Product Development and Digital Platform Operations with Leading Canadian Media Brands
Over Twenty Years of Leadership Experience in IT Systems Development & Adoption
Specialization in Operational and Organizational Transformation and Digital Platform Development
SME Entrepreneur
SEO plus – Test
20+ years at GSK, leading R&D activities on multiple vaccine programs
Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
Key areas of expertise are:
Process development of protein Biologics/Recombinant Antigens
Recombinant protein expression (mammalian, insect, yeast, bacterial)
Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
Protein Engineering and Structural Biology
Defining quality attributes, biophysical characterization of proteins, and analytical strategy
Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).